Mindesta is pleased to announce the collaboration between CTT Pharmaceutical Holdings Inc and Phytoplant Research, S.L.. Phytoplant Resesarch S.L. will provide CTT Pharmaceuticals Inc., novel unique extracts from their proprietary Cannabis varieties to manufacture novel quick dissolving oral wafers that offer the entourage therapeutic effects of [...]
Mindesta Inc. CTT Pharmaceuticals Inc. has issued an update from its president to shareholders. The update is as follows: To CTT Shareholders: Let me first take this opportunity to thank you for your continued interest in CTT Pharmaceuticals. Our gains have been a direct result of the continued support of shareholders like you. At this time, I [...]
The Board of Directors of Mindesta is pleased to announce the appointment of Dr. Stephen Houldsworth to it's advisory board of CTT Pharmaceuticals effective immediately: "I am pleased to be working with CTT in an advisory role as they work to create evidence based medicines within the Cannabis arena using their novel drug delivery systems. At a [...]
The Board of Directors of Mindesta is pleased to announce the appointment of Michelle Hamilton-Page, Digital Strategist, to the advisory board of CTT Pharmaceuticals effective immediately. "We value the addition of Ms. Hamilton-Page, as our holistic approach includes creating better adherence and safety for our future opioid based pain management [...]
The Board of Directors of Mindesta is pleased to announce the appointment of Michelle Hamilton-Page, Digital Strategist, to the advisory board of CTT Pharmaceuticals effective immediately. "We value the addition of Ms. Hamilton-Page, as our holistic approach includes creating better adherence and safety for our future opioid based pain management [...]
The Board of Directors of Mindesta is pleased to announce the appointment of Graham Wong to Vice President, Marketing of CTT Pharmaceuticals management team. "Part of CTT's strategy is to partner with cannabis producers with domestic legislative advantages. It was important for us to have the ability to properly design, package and market products [...]
The Board of Directors of Mindesta Inc. is pleased to announce the appointment of Lucie Lettellier to Chief Financial Officer (CFO) of CTT Pharmaceuticals, effective immediately. Lucie Letellier is a financial professional with specialization in finance and accounting. From 2005 to 2009 Lucie was the CFO of [...]
The Board of Directors of Mindesta is pleased to announce the appointment of Steve Abboud to the Advisory Board of CTT Pharmaceuticals, effective immediately. "As part of CTT's overall business strategy, we required a subject matter expert within the medicinal marijuana industry. Steve brings a wealth of knowledge in all facets of medicinal [...]
The Board of Directors of Mindesta today announced the appointment of Gilles Derome and Dr. Dana Allen as Advisory Board members of the firm - CTT Pharmaceuticals, effective immediately. Gilles Derome brings more than twenty-five years of marketing-sales and senior management experience in pharmaceuticals combined with consulting for [...]
Mindesta has closed on its acquisition of of CTT Pharmaceuticals, The Company, CTT Pharma and the shareholders of CTT Pharma executed a share exchange agreement which provide in part for the Company to acquire all the issued and outstanding shares of common stock of CTT Pharma in exchange for 149,183,285 shares of the Company's common stock. With [...]
Mindesta announces that it has completed a non brokered private placement consisting of the sale of 15,783,332 units at a price of US$0.015 per unit for total proceeds of US$236,750. Each unit consists of one common share and one half of a share purchase warrant. Each whole warrant entitles the holder to purchase one common share at a price of [...]
Mindesta wishes to provide information on the final taxable dividend per share and return of capital per share with respect to its January 25, 2012 distribution to shareholders. At the close of trading on January 25, 2012, Mindesta completed the distribution to the Company's shareholders of a majority of the shares of Northern Graphite Corporation [...]
